Condition (MeSH)
Exercise-Induced Allergies
ClinicalTrials.gov lists 55 trials for Exercise-Induced Allergies or a narrower condition beneath it. Organon and Co has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
4 of the 55 trials are tagged with Exercise-Induced Allergies itself; the rest are tagged with a narrower condition beneath it.
When did Exercise-Induced Allergies trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 5 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Exercise-Induced Allergies trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 3 | 11 |
| Phase 4 | 7 |
| Not applicable | 21 |
| Observational | 9 |
How many Exercise-Induced Allergies trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 36 |
| Terminated | 2 |
| Withdrawn | 4 |
| Unknown status | 11 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Exercise-Induced Allergies trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Organon and Co | 5 |
| GlaxoSmithKline | 4 |
| AstraZeneca | 2 |
| Bond Avillion 2 Development LP | 1 |
| Critical Therapeutics | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Exercise-Induced Allergies? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Montelukast | 4 |
| OPN-375 | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Comparator: Montelukast | 3 |
| Formoterol-budesonide | 2 |
| Methacholine challenge | 2 |
| Salmeterol / Fluticasone | 2 |
| Budesonide EC | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Exercise-Induced Allergies trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Accidental Overdose | 1 | 1 |
| Overdose | 1 | 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.